Velocity Clinical buys 2 clinical trial networks

By The Science Advisory Board staff writers

Velocity Clinical Research has acquired two companies that operate research trial networks: VitaLink Research and the National Research Institute (NRI). Velocity Clinical did not disclose the amount it paid for the firms.

Velocity said the combination of VitaLink and NRI will boost the company's therapeutic reach and recruiting power, with the goal of reaching more minority populations to serve as volunteers for clinical trials. Velocity will also provide additive business development effort and streamlined service delivery to the acquired companies.

Management from both companies will occupy leadership roles within Velocity. These include Steve Clemons, CEO of VitaLink, who becomes Velocity's new senior vice president of client delivery, and Samira Moran, CEO of NRI, who becomes Velocity's new senior vice president of specialist care delivery.

Copyright © 2021

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?